Framework for Analysing Risk in Health Technology Assessments and its application to managed
|Image: Risk by Sean Davis|
HTA 14/57/01: Olaparib for the maintenance treatment of relapsed, platinum-sensitive ovarian, fallopian tube and peritoneal cancer with BRCA 1 or 2 mutations following response to prior platinum-based chemotherapy [ID735]
HTA - 14/59/01: Sofosbuvir-ledipasvir for treating genotype 1 chronic hepatitis C [ID742]
An assessment of quality assessment and cost-effectiveness within an MCDA framework relating to Specialised Commissioning.